Oral infigratinib boosts growth velocity in achondroplasia study

1. Oral infigratinib achieved the highest growth velocity reported to date in a randomized achondroplasia trial, growing 2.10 cm/year faster than placebo.

2. The therapy demonstrated the first statistically significant improvement in upper-to-lower body proportionality for children with disproportionate short stature.

BridgeBio Pharma has released topline Phase 3 results for infigratinib, and the numbers are impressive for children with the most common form of dwarfism. The PROPEL 3 study showed that children taking the once-daily oral pill grew an average of 2.10 cm/year faster than those on placebo, meeting the primary endpoint with high significance. Perhaps more importantly for pediatricians and families, the drug showed a significant improvement in proportionality, helping to normalize the upper-to-lower body ratio that often causes orthopedic issues. This is the first time an oral small molecule has demonstrated such high growth velocity in a randomized trial. For specialists, infigratinib offers a non-injectable alternative to current therapies, which often require daily shots that are difficult for families to maintain. The drug targets the overactive FGFR3 receptor directly, treating the condition at its molecular source rather than just managing symptoms. BridgeBio is preparing to submit its marketing applications globally in the second half of 2026. While the linear growth is the headline, the long-term impact on spinal stenosis and sleep apnea remains a point of continued study. The absolute mean growth rate of 5.96 cm/year suggests a potential normalization of growth patterns during the pediatric window. No serious treatment-related adverse events were reported, which is a major relief for a chronic pediatric therapy. We don’t yet know if the proportionality gains will translate into better functional outcomes in adulthood or reduced surgical burden.

Image: PD

©2026 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.